Antifungal properties of Abnormal Cannabinoid derivatives: Disruption of Biofilm Formation and Gene Expression in Candida Species.

Abnormal cannabinoids Antifungal activity Biofilm Candida Cannabinoids Fluconazole resistance vulvovaginal candidiasis

Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
03 Oct 2024
Historique:
received: 19 06 2024
revised: 27 09 2024
accepted: 27 09 2024
medline: 6 10 2024
pubmed: 6 10 2024
entrez: 5 10 2024
Statut: aheadofprint

Résumé

Abnormal cannabinoids (including comp 3) are a class of synthetic lipid compounds with non-psychoactive properties and regioisomer configurations, but distinct from traditional cannabinoids since they do not interact with the established CB1 and CB2 receptors. Previous research showed the cardioprotective and anti-inflammatory potentials of comp 3 and more recently its antimicrobial effect on methicillin-resistant Staphylococcus aureus (MRSA). Given the escalating challenges posed by Candida infections and the rise of antifungal drug resistance, the exploration of novel therapeutic avenues is crucial. This study aimed to assess the anti-Candida properties of newly synthesized AbnCBD derivatives. AbnCBD derivatives were synthesized by acid catalysis-induced coupling and further derivatized. We evaluated the potential of the AbnCBD derivatives to inhibit the growth stages of various Candida species. By in vitro colorimetric assays and in vivo mice experiments, we have shown that AbnCBD derivatives induce differential inhibition of Candida growth. The AbnCBD derivatives, especially comp 3, comp 10, and comp 9 significantly reduced the growth of C. albicans, including FLC-resistant strains, and of C. tropicalis and C. parapsilosis but not of C auris compared to their controls (FLC and 0.5% DMSO). Comp 3 also disrupted C. albicans biofilm formation and eradicated mature biofilms. Notably, other derivatives of AbnCBD disrupted the biofilm formation and maturation of C. albicans but did not affect yeast growth. In a murine model of VVC, comp 3 demonstrated significant fungal clearance and reduced C. albicans burden compared to vehicle and FLC controls. These findings highlight the potential of AbnCBDs as promising antifungal agents against Candida infections.

Identifiants

pubmed: 39368567
pii: S1043-6618(24)00386-4
doi: 10.1016/j.phrs.2024.107441
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107441

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest none

Auteurs

Prince Ofori (P)

Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Natalia Zemliana (N)

Institute of Personalized and Translational Medicine, Department of Molecular Biology, Ariel University, Ariel, Israel.

Ilan Zaffran (I)

Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Tatiana Etzion (T)

Medicinal Chemistry Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Ronit Vogt Sionov (RV)

Biofilm Research Laboratory, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Doron Steinberg (D)

Biofilm Research Laboratory, The Faculty of Dental Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Raphael Mechoulam (R)

Medicinal Chemistry Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Natalya M Kogan (NM)

Institute of Personalized and Translational Medicine, Department of Molecular Biology, Ariel University, Ariel, Israel; Medicinal Chemistry Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: natalyak@ariel.ac.il.

Francesca Levi-Schaffer (F)

Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute of Drug Research, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.

Classifications MeSH